Compare · ARGX vs BSEM

ARGX vs BSEM

Side-by-side comparison of argenx SE (ARGX) and BioStem Technologies Inc. (BSEM): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ARGX and BSEM operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • ARGX is the larger of the two at $59.02B, about 3205.5x BSEM ($18.4M).
  • Over the past year, ARGX is up 2.4% and BSEM is down 73.3% - ARGX leads by 75.7 points.
  • BSEM has been more active in the news (9 items in the past 4 weeks vs 6 for ARGX).
  • ARGX has more recent analyst coverage (25 ratings vs 0 for BSEM).
PerformanceARGX+9.91%BSEM-73.31%
2026-08-07+0.00%2026-11-16
MetricARGXBSEM
Company
argenx SE
BioStem Technologies Inc.
Price
-
-
Market cap
$59.02B
$18.4M
1M return
+16.06%
-53.03%
1Y return
+2.36%
-73.31%
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2017
News (4w)
6
9
Recent ratings
25
0
ARGX

argenx SE

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

BSEM

BioStem Technologies Inc.

BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain, CryoTek and SteriTek processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.

Latest ARGX

Latest BSEM